APX 001

Drug Profile

APX 001

Alternative Names: APX-001 - Amplyx Pharmaceuticals

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eisai Co Ltd
  • Developer Amplyx Pharmaceuticals
  • Class Antifungals; Small molecules
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Coccidioidomycosis; Candidiasis; Mycoses; Aspergillosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Mycoses

Most Recent Events

  • 02 Aug 2017 Amplyx Pharmaceuticals plans phase II trials for Aspergillosis and Candidiasis in early 2018 (Amplyx Pharmaceuticals website, August 2017)
  • 01 Jul 2017 Amplyx Pharmaceuticals completes a phase I trial in Mycoses in Netherlands (IV) (NCT02956499)
  • 20 Apr 2017 Amplyx Pharmaceuticals completes a phase I trial in Healthy volunteers in Netherlands (PO) (IV) (NCT02957929)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top